GSK to Acquire Canadian BELLUS Health for Around $2 Billion
April 18 2023 - 2:48AM
Dow Jones News
By Michael Susin
GSK PLC said Tuesday that it has reached an agreement to buy the
late-stage biopharmaceutical company BELLUS Health Inc. for $14.75
a share in cash, representing a total equity value of around $2.0
billion.
The pharmaceutical giant said the deal will provide access to
camlipixant, a treatment for refractory chronic cough currently in
phase III development.
Following the anticipated regulatory approval and launch of
camlipixant in 2026, the acquisition of the Canada-based company is
expected to be accretive to adjusted earnings per share--which
strips out exceptional and other one-off items--from 2027 and has
the potential to deliver significant sales through 2031 and beyond,
it added.
"This proposed acquisition complements our portfolio of
specialty medicines and builds on our expertise in respiratory
therapies," Chief Commercial Officer Luke Miels said.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
April 18, 2023 02:33 ET (06:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024